Video

Dr. Evens on Key Highlights from the RWJ Annual Clinical Practice and Research Summit

Andrew M. Evens, DO, MSc, discusses highlights from the 2021 RWJ Annual Clinical and Practice Research Summit.

Andrew M. Evens, DO, MSc, director for clinical services, Rutgers Cancer Institute of New Jersey, system director of Medical Oncology, oncology lead, Combined Medical Group with RWJBarnabas Health, associate vice chancellor, Clinical Innovation and Data Analytics, Rutgers Biomedical and Health Sciences, discusses highlights from the 2021 RWJ Annual Clinical and Practice Research Summit.

The first annual meeting, hosted by RWJ Barnabas Health, covered a host of topics, spanning from hematologic malignancies, multiple myeloma, breast and gynecologic cancers, brain stereotactic radiation therapy, and cellular immunotherapy, Evens says. Moreover, there are multiple disease breakout sessions that were held, in which investigators discussed current trends in particular paradigms, as well as new clinical trials, Evens adds.

Every topic discussed during the summit was anchored in clinical care and the current worldwide standard of care, in the context of current, cutting-edge clinical research being done at RWJBarnabas Health, Evens concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
Dr Fakih on the Future of Botensilimab and Balstilimab–Based Therapies in MSS mCRC
Alberto Montero, MD, MBA, CPHQ
Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute
Taliya Lantsman, MD, a hematology/oncology fellow at Beth Israel Deaconess Medical Center
Alvaro Alencar, MD, discusses current unmet needs following the development of covalent BTK inhibitor resistance in CLL.
Melanie A. Sheen, MD
Raajit Rampal, MD, director of the Center for Hematologic Malignancies and director of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center